

**CURRICULUM VITAE**  
**Javid J. Moslehi, M.D.**

**OFFICE ADDRESS:** William Grossman Distinguished Professor in Cardiology  
Chief, Section of Cardio-Oncology & Immunology  
Professor in Residence  
University of California, San Francisco (UCSF) School of Medicine

Smith Cardiovascular Research Building  
Cardiovascular Research Institute (CVRI)  
555 Mission Bay Blvd., South, Mail Code 3118  
San Francisco, CA 94143-3118

**OFFICE PHONE NO.:** 415-502-3119

**EMAIL:** [javid.moslehi@ucsf.edu](mailto:javid.moslehi@ucsf.edu)

**DATE & PLACE OF BIRTH:** June 16, 1975; Tehran, Iran

**EDUCATION**

09/1992-06/1996	B.A. (Biology) Johns Hopkins University, Baltimore, MD
07/1998-06/1999	Sarnoff Fellow: Harvard Medical School, Boston, MA
08/1996-06/2001	M.D. University of Connecticut School of Medicine, Farmington, CT
07/2001-06/2002	Intern: Internal Medicine, Johns Hopkins Hospital, Baltimore, MD
07/2002-06-2004	Resident: Internal Medicine, Johns Hopkins Hospital, Baltimore, MD
07/2004-06/2007	Clinical Fellow, Cardiovascular Medicine Brigham and Women's Hospital, Harvard Medical School, Boston, MA
07-2007-05/2014	Research Fellow, Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (Laboratory of Nobel Laureate Dr. William G. Kaelin, Jr.)

**LICENSURE AND CERTIFICATION**

2004	American Board of Internal Medicine, Internal Medicine
2005	Massachusetts Registered Physician License #223358
2010	American Board of Internal Medicine, Cardiovascular Disease
2014	Tennessee Physician License #52008
2021	Medical Board of California C174811

**ACADEMIC APPOINTMENTS**

07/2009-06/2014	Instructor of Medicine Harvard Medical School Boston, MA
06/2014-05/2019	Assistant Professor of Medicine Vanderbilt School of Medicine Nashville, TN
05/2019-09/2021	Associate Professor of Medicine (with Tenure) Vanderbilt School of Medicine Nashville, TN

10/2021-06/2022 Associate Professor in Residence  
University of California, San Francisco School of Medicine  
San Francisco, CA

07/2022-Present Professor in Residence  
University of California, San Francisco School of Medicine  
San Francisco, CA

### **HOSPITAL APPOINTMENTS**

07/2009-06/2014 Associate Physician  
Cardiovascular Medicine  
Brigham and Women's Hospital  
Boston, MA

07/2009-06/2014 Associate Physician  
Cardiovascular Medicine  
Dana-Farber Cancer Institute  
Boston, MA

07/2009-06/2014 Co-Director, Cardio-Oncology Program  
Brigham and Women's Hospital  
Dana-Farber Cancer Institute  
Boston, MA

06/2014-10/2021 Associate Physician  
Vanderbilt University Medical Center  
Nashville, TN

06/2014-10/2021 Director, Cardio-Oncology Program  
Vanderbilt Heart and Vascular Institute  
Vanderbilt-Ingram Cancer Center  
Nashville, TN

08/2019-10/2021 Co-Director, Vanderbilt Program for Optimizing Immuno-Oncology  
Therapy (V-POINT)  
Vanderbilt University Medical Center  
Nashville, TN

10/2021-Present Section Chief, Cardio-Oncology & Immunology  
University of California, San Francisco (UCSF) School of Medicine  
San Francisco, CA

03/2023-Present Director, UCSF Center for Myocarditis  
University of California, San Francisco (UCSF) School of Medicine  
San Francisco, CA

### **PROFESSIONAL ORGANIZATIONS**

1999-Present Stanley J. Sarnoff Society of Fellows, Member  
2004-Present Massachusetts Medical Society, Member

2005-Present American Heart Association (AHA), Member  
2005-Present American College of Cardiology (ACC), Member  
2020-Present American Society of Clinical Investigation (ASCI), Elected Member

## **PROFESSIONAL ACTIVITIES**

### **Intramural**

07/2009-06/2014 Co-Director, Cardio-Oncology Program  
Brigham and Women's Hospital, Boston, MA  
Dana-Farber Cancer Institute, Boston, MA

06/2014-09/2021 Director, Cardio-Oncology Program  
Vanderbilt Heart and Vascular Institute  
Vanderbilt-Ingram Cancer Center, Nashville, TN

07/2017-09/2021 Program Director, Cardio-Oncology Fellowship  
Vanderbilt University Medical Center  
San Francisco, CA

08/2019-09/2021 Co-Director, Vanderbilt Program for Optimizing Immuno-Oncology  
Therapy (V-POINT)  
Vanderbilt University Medical Center  
Nashville, TN

10/2021-Present Section Chief, Cardio-Oncology, Immunology and Metabolism  
University of California, San Francisco (UCSF) School of Medicine  
San Francisco, CA

10/2021-Present Program Director, Cardio-Oncology Fellowship  
University of California, San Francisco (UCSF) School of Medicine  
San Francisco, CA

07/2022-Present Associate Program Director (Research), Cardiology Fellowship  
University of California, San Francisco (UCSF) School of Medicine  
San Francisco, CA

07/2022-Present Associate Director, UCSF CVRI T32 Grant  
University of California, San Francisco (UCSF) School of Medicine  
San Francisco, CA

07/2023-Present UCSF Cardiovascular Research Institute (CVRI) Executive Committee  
University of California, San Francisco (UCSF) School of Medicine  
San Francisco, CA

### **Extramural**

05/2011-06/2023 Sarnoff Foundation: Scientific Committee, Board of Directors  
Sarnoff Foundation  
Great Falls, VA

11/2013-06/2008 National Cancer Institute (NCI) Oncology Cardiotoxicity Task Force  
Bethesda, MD

11/2013-10/2021	National Comprehensive Cancer Network (NCCN) Survivorship Panel Guidelines Committee, Cardio-Oncology Guidelines Committee, Cancer Survivorship Fort Washington, PA
05/2015-06/2008	American Society of Clinical Oncology (ASCO) Cardiac Dysfunction Screening Working Group Alexandria, VA
04/2019-07/2021	Chair, AHA Cardio-Oncology Science Subcommittee American Heart Association (AHA) Dallas, TX
08/2023-Present	Medical Advisory Board Myocarditis Foundation Kingwood, TX

**Study Section/Research Advisory Committee Appointments**

2014	Alberta Cancer Foundation Ad Hoc Grant Reviewer
2017	National Institute of Health - NCI Provocative Questions (PQ) Study Section Ad Hoc Grant Reviewer
2018	Parker Institute for Immunotherapy Ad Hoc Grant Reviewer
2018-2019	Foundation Pour La Recherche Medicale (FRM) Ad Hoc Grant Reviewer
2019	National Institute of Health - NHLBI Small Business Innovation Research (SBIR) Study Section Ad Hoc Grant Reviewer
2019	Department of Defense - DOD Breast Cancer Research Program (BCRP) Pathobiology (PB-4) Ad Hoc Grant Reviewer
2020	National Institute of Health - NHLBI Clinical and Integrative Cardiovascular Sciences (CICS) Study Section Ad Hoc Grant Reviewer
2020	National Institute of Health - NHLBI Small Business Innovation Research (SBIR) Study Section Ad Hoc Grant Reviewer
2020	National Institute of Health - NHLBI Clinical and Integrative Cardiovascular Sciences (CICS) Study Section Ad Hoc Grant Reviewer
2020	National Institute of Health - NCI NCI Provocative Questions (#4: sex differences in cancer) Study Section Ad Hoc Grant Reviewer
2021	National Institute of Health - NHLBI Clinical Integrative Cardiovascular and Hematological Sciences (CCHS) Ad Hoc Grant Reviewer
2021-2025	National Institute of Health - NHLBI Clinical Integrative Cardiovascular and Hematological Sciences (CCHS)

Standing Member

**Editorial Activities**

**Associate Editor**

02/2021-07/2022      Circulation Research  
08/2023-Present      Circulation, Guest Editor Team

**Editorial Board**

10/2020-Present      Circulation

**Editorial Consultant**

06/2018-Present      JACC: Basic to Translational Science (JACC BTS)

**Guest Editor**

Cardiovascular Research – Compendium in Cardio-Oncology (2019)  
Journal of Molecular and Cellular Cardiology – Cardio-Oncology Special Issue (2021)

**Ad Hoc Reviewer**

New England Journal of Medicine, Science, Cell, Nature, Science Translational Medicine, Nature Medicine, Journal of American Medical Association (JAMA), Circulation, Journal of Clinical Oncology, Journal of American College of Cardiology, Circulation Research, European Heart Journal, Journal of Molecular and Cellular Cardiology, Arteriosclerosis, Thrombosis and Vascular Biology (ATVB), Journal of Clinical Oncology, PLoS, Journal of the American Heart Association, Annals of Oncology, Bone Marrow Transplantation, Journal of Heart Failure, Clinical Cancer Research, Vascular Medicine

**Honors and Awards**

1994    Fortuna Iseman Klotz Memorial Scholarship: Johns Hopkins University  
1996    Azrael Fellowship for Excellence in Journalism: Johns Hopkins University  
1998    Stanley J. Sarnoff Fellowship in Cardiovascular Research  
2006    Harvard Medical School Resident Teaching Award  
2009    Thomas W. Smith Fellowship Award in Heart Failure Research  
         Brigham and Women’s Hospital, Division of Cardiology  
2009    Watkins Discovery Award Program in Cardiovascular Medicine  
         Brigham and Women’s Hospital, Division of Cardiology  
2009    Heart Failure Society of America Research Fellowship Award  
2010    Lerner Research Award, Brigham and Women’s Hospital  
2016    Stanley J. Sarnoff Alumni Achievement Award  
2016    Vanderbilt Biomedical Science Impact Award  
2020    American Society of Clinical Investigation (ASCI), Elected Member  
2021    Inaugural Holder of the William Grossman Distinguished Chair in Cardiology, UCSF

**TEACHING ACTIVITIES**

2005-2006      Harvard Medical School - Integrated Physiology  
                         1<sup>st</sup> year Harvard Medical Students  
2015-2021      Vanderbilt University Medical Center  
                         Cardiovascular Disease Integrated Sciences Course  
2019-2021      Vanderbilt University Medical Center  
                         Interdisciplinary Graduate Program (IGP) in the Biological and Biomedical  
                         Sciences - Signal Transduction in Disease

## **Research Mentorship**

2010-2011	Babak Nazer, Resident, Brigham and Women's Hospital Currently: Associate Professor, University of Washington
2010-2012	Steven Bair, Sarnoff Fellow, Medical Student, Case Western Currently: Assistant Professor, University of Colorado
2011-2013	Amanda Tong, Post-Doctoral Fellow, Cardio-Oncology (Brigham) Currently: Assistant Professor, UTSW
2011-2013	Alan Baik, Sarnoff Fellow, Medical Student, UCSF Currently: Assistant Professor, UCSF
2011-2014	John Groarke, Cardio-Oncology Fellow (Brigham) Currently: Director, Cardiometabolic Clinical Research, Pfizer
2015-2019	Michael Litt, MD/PhD Student, Vanderbilt (Co-mentorship, Roger Cone) Currently: Cardiology Fellow, University of Pennsylvania
2015-2018	Mary Barber, Undergraduate Student, Belmont University Currently: Medical Student, Harvard Medical School
2016-2018	G. Donald Okoye, Post-Graduate Student/Technician Currently: MD/PhD Student, Vanderbilt
2017-2018	Joe-Elie Salem, Cardio-Oncology Fellow, Vanderbilt Currently: Professor, Sorbonne University, Director, Cardio-Oncology, APHP6, Hopitaux de Paris, Paris, France
2018-2019	Elishama Kanu, Medical Student, Vanderbilt Currently: Resident, Surgery, Duke
2018-2019	Ayush Sangari, Undergraduate Student, Vanderbilt Currently: Medical Student, Stony Brook School of Medicine
2018-2019	Zhan "Jack" Rong, Undergraduate Student, Vanderbilt Currently: Medical Student, UCSD
2019-2020	Wouter Meijers, M.D., Ph.D., Cardio-Oncology Fellow, Vanderbilt Currently: Cardiology Fellow, University of Groningen
2019-2020	Elles Screever, M.D., Ph.D., MD/PhD Student, University of Groningen (Holland) and Vanderbilt
2019-2021	Ali Manouchehri, M.D., Clinical Pharmacology Fellow, Vanderbilt Currently: Clinical Research Scientist, Hookipa Pharmaceuticals
2019-2021	John Power, Resident, Vanderbilt Currently: Cardiology Fellow, UCSD
2019-2021	Jiun-Ruey Hu, Resident, Vanderbilt Currently: Cardiology Fellow, Yale
2019-2021	Arrush Choudhary, Medical Student, Vanderbilt Currently: Internal Medicine Resident, BIDMC
2019-2021	Warren Tai, Resident, Vanderbilt Currently: Cardiology Fellow, UCLA
2020-2021	Joseph Nowatzke, Resident, Vanderbilt Currently: Cardiology Fellow, Vanderbilt
2020-2021	Olusola Orimoloye, Resident, Vanderbilt Currently: Cardiology Fellow, Northwestern
2020-Present	Matthew Fleming, Cardiology Fellow, Vanderbilt
2020-Present	Kaushik Amancherla, Cardiology Fellow, Vanderbilt
2020-Present	Juan Qin, Post-Doctoral Fellow, Vanderbilt/UCSF
2020-Present	Andrew Hughes, Resident, Vanderbilt
2022-Present	Shaoyi Zhang, Post-Doctoral Fellow, UCSF
2022-Present	Amir Munir, Cardiology/Cardio-oncology Fellow, UCSF
2022-Present	Yen-Chou Chen, Cardio-oncology Fellow, UCSF

2023-Present Alan Gutierrez, Sarnoff Fellow (Yale Medical Student)

### **Cardio-Oncology Fellowship**

The following individuals have completed a clinical cardio-oncology fellowship under my supervision. In 2017, I formalized a curriculum in cardio-oncology and obtained GME approval for a cardio-oncology fellowship at Vanderbilt. I have set up a similar formalized fellowship at UCSF.

2012-2013	Matthew McGuiness, M.D. Subsequent Job: Assistant Professor, University of Massachusetts
2013-2014	John Groarke, M.D. Subsequent Job: Assistant Professor, Medicine, Harvard Medical School
2016-2017	Nirmanmoh Bhatia, M.D. Subsequent Job: Private Practice, Birmingham, Alabama
2017-2018	Kristopher Swiger, M.D. Subsequent Job: Private Practice, Wilmington, NC
2017-2018	Wendy Bottinor, M.D. Subsequent Job: Assistant Professor, Virginia Commonwealth University
2017-2018	Joe-Elie Salem, M.D., Ph.D. Subsequent Job: Associate Professor, Sorbonne University Director, Cardio-Oncology, APHP6, Hopitaux de Paris, Paris, France
2018-2019	Weijuan Li, M.D. Subsequent Job: Private Practice, Lynchburg, Virginia
2019-2020	Wouter Meijers, M.D., Ph.D. Subsequent Job: Assistant Professor, University of Groningen, Holland
2020-2021	Amar Parikh, M.D. Subsequent Job: Private Practice, Charlotte, NC
2020-2021	Isik Turker, M.D. Subsequent Job: Assistant Professor, Washington Univ, St Louis, MO
2021-2022	Matthew Fleming, M.D., Ph.D. Subsequent Job: Instructor, Vanderbilt University Medical Center
2022-2023	Yen-Chou Chen, M.D., MBA Subsequent Job: Program Leader, Cardio-Oncology, Assistant Professor, Taipei Medical University Hospital
2022-Present	Amir Munir, M.D.

### **RESEARCH PROGRAM**

#### **Funding - Current**

2023-Present	NIH R01 HL170038 Novel biomarkers and mechanisms of TKI associated cardiotoxicity. Project Period: 9/1/23-12/31/27 Role: Co-Investigator (PI: Daniel Addison)
2022-Present	NIH R01 HL160688 [18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and ICI therapy Project Period: 1/1/22-12/31/26 Role: Co-Investigator (MPI: Youngho Seo, Jeleni Levi)
2021-Present	NIH R01 HL156021

Immunologic and antigenic drivers of immune checkpoint inhibitor-associated myocarditis

Total Funding: \$4,000,773 (\$2,320,448 direct)

Project Period: 5/1/21-4/30/26

Role: Principal Investigator (MPI – Justin Balko)

2021-Present

NIH R01 HL155990

Long-term cardiovascular sequelae of cancer immunotherapies

Total Funding: \$4,091,030 (\$2,372,797 direct)

Project Period: 3/1/21-2/28/26

Role: Principal Investigator (MPI – Douglas Johnson)

2019-Present

NIH R01 HL141466

Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension

Total Funding: \$3,402,840 (\$2,001,670 direct)

Project Period: 8/1/19-5/31/24

Role: Principal Investigator

2019-Present

NIH R01 CA227481

Patient and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition

Project Period: 4/1/19-3/31/24

Role: Co-Investigator (MPI: Justin Balko, Doug Johnson)

## **PUBLICATIONS AND PRESENTATIONS**

**Total: >260 Publications. H-Index: 85, Citations: >31000**

### **Peer Reviewed Articles**

Following represent abridged version of most significant original publications:

1. Peng SL, **Moslehi J**, Craft J. Roles of Interferon-gamma and Interleukin-4 in Murine Lupus. **J Clin Invest.** 1997;99(8):1936-46. PMID: 9109438
2. Fatenejad S, Bennett M, **Moslehi J**, Craft J. Influence of Antigen Organization on the Development of Lupus Autoantibodies. **Arthritis Rheum.** 99841(4):603-12. PMID: 9550469
3. Peng SL, **Moslehi J**...Craft J. Perforin Protects Against Autoimmunity in Lupus-prone Mice. **Journal of Immunology.** 1998;160(2):652-60. PMID: 9551899
4. Ohh M, Kim WK, **Moslehi J**...Kaelin WG Jr. An Intact NEDD8 Pathway is Required for Cullin-Dependent Ubiquitylation in Mammalian Cells. **EMBO Rep.** 2002;3(2):177-82. PMID: 11818338
5. Hansen WJ, Ohh M, **Moslehi J**...Kaelin WG Jr., Welch WJ. Diverse Effects of Mutations in Exon II of the Von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cystolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity. **Mol. Cell. Biol.** 2002;22(6):1947-60. PMID: 11865071
6. Takimoto E...**Moslehi J**...Kass DA. cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism. **Circ Res.** 2005;96(1):100-9. PMID: 15576651
7. Minamishima YA, **Moslehi J**...Kaelin WG Jr. Somatic Inactivation of the PHD2 Prolyl Hydroxylase Causes Polycythemia and Congestive Heart Failure. **Blood.** 2008;111(6):3236-44. PMID: 18096761



8. Minamishima YA, **Moslehi J**...Kaelin WG Jr. A Feedback Loop Involving the PHD3 Prolyl Hydroxylase Tunes the Mammalian Hypoxic Response in Vivo. *Mol Cell Biol.* 2009;29(21):5729-41. PMID: 19720742
9. **Moslehi J**, Minamishima YA...Liao R, Kaelin WG Jr. Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy. *Circulation.* 2010;122(10):1004-16. PMID: 20733101
10. Sahin E, Colla S, Lissa M, **Moslehi J**...Depinho R. Telomere Dysfunction Induces Metabolic and Mitochondrial Compromise. *Nature.* 2011;475(7355):254. PMID: 21307849
11. Richards CJ...**Moslehi J**, Choueiri T. Incidence and Risk of Congestive Heart Failure in Patients with Renal and Nonrenal Cell Carcinoma Treated with Sunitinib. *J Clin Oncol.* 2011;29(25):3450-6. PMID: 21810682
12. Uraizee I, Cheng S, **Moslehi J**. Reversible Cardiomyopathy Associated with Sunitinib and Sorafenib. *New England Journal of Medicine.* 2011;470(7334):359-65. PMID: 22030001
13. Querbes W, Bogorad RL, **Moslehi J**...Kaelin WG Jr. Treatment of Erythropoietin Deficiency with Systemically Administered siRNA. *Blood.* 2012;120(9):1916-22. PMID: 22611156
14. Icli B, Wara AK, **Moslehi J**...Feinberg MW. MicroRNA-26a Regulates Pathological and Physiological Angiogenesis by Targeting BMP/SMAD1 Signaling. *Circ Res.* 2013;113(11):1231-41. PMID: 24047927
15. Liu D...**Moslehi J**...Dietz HC, Germino GG, Watnick T. A Pkd1-Fbn1 Genetic Interaction Implicates TGF- $\beta$  Signaling in The Pathogenesis of Vascular Complications in Autosomal Dominant Polycystic Kidney Disease. *J Am Soc Nephrol.* 2014;25(1):81-91. PMID: 24071006
16. Gomes AP...**Moslehi J**...Sinclair DL. Declining NAD(+) Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication During Aging. *Cell.* 2013;155(7):1624-38. PMID: 24360282
17. Akbay EA, **Moslehi J**...Kaelin WG Jr, Bardeesy N, Wong K-K. D-2-Hydroxyglutarate Produced by Mutant IDH2 Causes Cardiomyopathy and Neurodegeneration in Mice. *Genes Dev.* 2014;28(5):479-90. PMID: 24589777
18. Zheng X...**Moslehi J**...Kaelin WG Jr, Zhang Q. Prolyl Hydroxylation by EglN2 Destabilizes FOXO3a by Blocking its Interaction with the USP9x Deubiquitinase. *Genes Dev.* 2014;28(13):1429-44. PMID: 24990963
19. Olenchock BA\*, **Moslehi J**\*, Baik A, Davidson S, Williams J, Gibson WJ, Chakraborty AA, Pierce K, Miller C, Hanse E, Kelekar A, Sullivan L, Wagers A, Clish C, Vander Heiden MG, Kaelin WG Jr. (\*Co-First Authors) Inhibition of the EglN1 Oxygen Sensor and Rerouting of  $\alpha$ -Ketoglutarate are Sufficient for Remote Ischemic Protection. *Cell.* 2016;165(2):497. PMID: 27058668
20. Johnson DB, Balko JM...Sosman JA, **Moslehi JJ**. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. *New England Journal of Medicine.* 2016;375(18):1749-1755. PMID: 27806233
21. Sarosiek KA...**Moslehi J**, Letai A. Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age and Tissue Specific Sensitivity to Cancer Therapeutics. *Cancer Cell.* 2017;31(1):142-156. PMID: 28017613
22. **Moslehi JJ**, Johnson DB, Sosman JA. Myocarditis with Immune Checkpoint Blockade. *New England Journal of Medicine.* 2017;376(3):292. PMID: 28099832
23. Sharma A, Burridge PW...**Moslehi JJ**, Mercola M, Wu JC. High-Throughput screening of Tyrosine Kinase Inhibitor Cardiotoxicity with Human Induced Pluripotent Stem Cells. *Science Translational Medicine.* 2017;9(377). PMID: 28202772

24. Lampson BL...**Moslehi JJ**, Brown JR. Ventricular Arrhythmias and Sudden Death in Patients Taking Ibrutinib. ***Blood***. 2017;129(18):2581-2584. PMID: 28223277
25. Brown JR, **Moslehi J**...Burger JA. Characterization of Atrial Fibrillation Adverse Events Reported in Ibrutinib Randomized Controlled Registration Trials. ***Haematologica***. 2017;102(10):1796-1805. PMID: 28751558
26. Litt MJ...**Moslehi J**, Cone RD. Loss of The Melanocortin-4 Receptor in Mice Causes Dilated Cardiomyopathy. ***Elife***. 2017;6. PMID: 28829041
27. **Moslehi JJ**, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis. ***Lancet***. 2018; 391(10124):933. PMID: 29536852
28. McBrayer SK...**Moslehi J**...Kaelin WG Jr. Autochthonous Tumors Driven by Rb1 Loss Have an Ongoing Requirement for the RBP2 Histone Demethylase. ***Proc Natl Acad Sci U S A***. 2018;115(16):E3741-E3748. PMID: 29610306
29. Salem JE...**Moslehi JJ**...Funk-Brentano C. Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. ***Circulation***. 2018;138(1):110-113. PMID: 29967236
30. Wang DY, Salem JE...**Moslehi JJ**, Johnson DB. Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. ***JAMA Oncol***. 2018. PMID: 30242316
31. Wright JJ, Salem JE...**Moslehi J**, Powers AC. Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. ***Diabetes Care***. 2018;41(12):e150-e151. PMID: 30305348
32. Anquetil C, Salem JE...**Moslehi JJ**, Allenbach Y. Immune Checkpoint Inhibitor-Associated Myositis. ***Circulation***. 2018;138(7):743-745. PMID: 30359135
33. Salem JE...Johnson DB, **Moslehi JJ**. Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study. ***Lancet Oncol***. 2018; 19(12):1579-1589. PMID: 30442497
34. Brown JR, **Moslehi J**...Valentino R. Incidence of and Risk Factors for Major Haemorrhage in Patients Treated with Ibrutinib: An Integrated Analysis. ***Br J Haematol***. 2019;184(4):558-569. PMID: 30506764
35. Latifi Y...**Moslehi J**...Lindner JR. Thrombotic Microangiopathy as a Cause of Cardiovascular Toxicity from the BCR-ABL1 Tyrosine Kinase Inhibitor Ponatinib. ***Blood***. 2019;133(14):1597-1606. PMID: 30692122
36. Cornell RF...**Moslehi J**...Lenihan D. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. ***J Clin Oncol***. 2019;37(22):1946-1955. PMID: 31188726
37. Salem JE...**Moslehi JJ**, Kerneis M. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. ***New England Journal of Medicine***. 2019;380(24):2377-2379. PMID: 31189043
38. Johnson DB...**Moslehi JJ**...Balko JM. A Case Report of Clonal EBV-like Memory CD4+ T Cell Activation in Fatal Checkpoint Inhibitor-induced Encephalitis. ***Nature Medicine***. 2019;25(8):1243-1250. PMID: 31332390
39. Salem JE, Yang T, **Moslehi JJ**...Rodén DM. Androgenic Effects on Ventricular Repolarization: A Translational Study from the International Pharmacovigilance Database to iPSC-Cardiomyocytes. ***Circulation***. 2019;140(13):1070-1080. PMID: 31378084
40. Bonaca MP...**Moslehi J**. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. ***Circulation***. 2019;140(2):80-91. PMID: 31390169
41. Salem JE...**Moslehi JJ**. Cardiovascular Toxicities Associated with Ibrutinib. ***J Am Coll Cardiol***. 2019;74(13):1667-1678. PMID: 31558250

42. Zaha VG, Meijers WC, **Moslehi J**. Cardio-Immuno-Oncology. *Circulation*. 2020;141(2):87-89. PMID: 31928434
43. Salem J...**Moslehi JJ**. Cardiac Events Associated with Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective. *J Am Coll Cardiol*. 2020;75(19):2521-2523. PMID: 32408984
44. Nguyen LS...**Moslehi JJ**...Salem J. Cardiovascular Toxicities Associated with Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database *Circulation*. 2020. PMID: 32442023
45. Johnson DB...**Moslehi JJ**. Immune Checkpoint Inhibitor Toxicities: Systems-based Approaches to Improve Patient Care and Research. *Lancet Oncol*. 2020;21(8):e398-e404. PMID: 32758477
46. Li C...**Moslehi JJ**, Ammirati E, Wang DW. Longitudinal Correlation of Biomarkers of Cardiac Injury, Inflammation, and Coagulation to Outcome in Hospitalized COVID-19 Patients. *J Mol Cell Cardiol*. 2020;147:74-87. PMID: 32827510
47. Xiao L, Salem JE...**Moslehi JJ**, Nahrendorf M, Ellinor PT, Milan DJ. Ibrutinib-Mediated Atrial Fibrillation Due to Inhibition of CSK. *Circulation*. 2020;142(25):2443-2455. PMID: 33092403
48. Wei SC, Meijers WC...**Moslehi JJ\***, Allison JP\* (\*Co-Senior/Co-Corresponding). A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. *Cancer Discovery*. 2021;11(3):614-625. PMID: 33257470
49. Amancherla K, Qin J...**Moslehi JJ**. RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets. *Circ Res*. 2021. PMID: 34126013.
50. Lehmann LH...Salem JE, **Moslehi JJ**. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. *JAMA Cardiol*. 2021. PMID: 34232253
51. Salem JE, Nguyen LS, **Moslehi JJ**...Gougis P. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. *Eur Heart J*. 2021.42(38):3915-3928. PMID: 34370839.
52. Choudhary A...**Moslehi J**. PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation. *Circulation: Heart Failure*. 2021;14(10):e008563. PMID: 34558299
53. Brown JR...**Moslehi J**, Furman RR. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. *Haematologica*. 2021. PMID: 34587719
54. Power JR...**Moslehi J\***, Salem JE\*; International ICI-Myocarditis Registry. (\*Co-Senior/Co-Corresponding). Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. *Circulation*. 2021.144(18):1521-1523. PMID: 34723640
55. Nguyen LS...**Moslehi JJ**, Salem JE. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. *Nature Communications*. 2022.13(1):25. PMID: 35013204
56. Rini BI, **Moslehi JJ**...Larkin J. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients with Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. *Journal of Clinical Oncology*. 2022. PMID:35239416
57. Nguyen LS...**Moslehi J**...Salem JE. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. *J Immunother Cancer*. 2022.10(4). PMID: 35383117

58. Szczepaniak P...**Moslehi J**...Guzik TJ. Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism. **Journal of Clinical Investigation**. 2022.132(13). PMID: 35617030
59. Naqash AR...**Moslehi JJ**, Sharon E. Major Adverse Cardiac Events with Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. **Journal of Clinical Oncology**. 2022. PMID: 35658474
60. Nowatzke J... **Moslehi J\***, Salem JE\*; International ICI-Myocarditis Registry. (\*Co-Senior/Co-Corresponding). Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. **European Journal of Cancer**. 2022.177:197-205. PMID: 36030143
61. Zhang Y...Yang L\*, **Moslehi JJ\***, Lin C\* (\*Co-Senior/Co-Corresponding). Hormonal Therapies Upregulate MANF and Overcome Female Susceptibility to Immune Checkpoint-Inhibitor (ICI)-Myocarditis. **Science Translational Medicine**. 2022. PMID: 36322628
62. Spetz JC...**Moslehi JJ**, Sarosiek KA. Heightened apoptotic priming of vascular cells across tissues and lifespan predisposes them to cancer therapy-induced toxicities. **Science Advances**. 2022. PMID: 36351019
63. Axelrod ML...**Moslehi JJ\***, Balko JM\* (\*Co-Senior/Co-Corresponding). Cytotoxic T cells specific for alpha-myosin drive myocarditis related to loss of immune checkpoint function. **Nature**. 2022.611:818-826. PMID: 36385524
64. Amancherla K...Tucker NR\*, **Moslehi J\***. Single-Nuclear RNA Sequencing of Endomyocardial Biopsies Identifies Persistence of Donor-Recipient Chimerism With Distinct Signatures in Severe Cardiac Allograft Vasculopathy. **Circulation: Heart Failure**. 2023. PMID: 36524467
65. Salem JE...**Moslehi JJ**...Allenbach Y. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. **Cancer Discovery**. 2023. 13:1100-1115. PMID: 36815259
66. Lehmann LH...**Moslehi J**...Salem JE. Cardiomyocardial Biomarkers in the Diagnosis Prognostication of Immune Checkpoint Inhibitor Myocarditis. **Circulation**. 2023.148:473-486. PMID: 37317858
67. Regnier P...**Moslehi J**...Saadoun D. CTLA-4 pathway is Instrumental in giant cell arteritis. **Circulation Research**. 2023.133:298-312. PMID: 37435729
68. Fenioux C...**Moslehi JJ**...Salem JE. Thymic alterations and susceptibility to immune checkpoint inhibitor myocarditis. **Nature Medicine**. 2023. 29:3100-3110. PMID: 37884625.
69. Ma P... **Moslehi JJ\***, Lavine KL\* (\*Co-Senior/Co-Corresponding). Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. **Circulation**. 2024. 149:48-66. PMID: 37746718

## Reviews/Editorials

Most Significant:

1. Nazer B, Humphreys BD, **Moslehi J**. Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular System: Focus on Hypertension. **Circulation**. 2011;124(15):1687-91. PMID: 21986775
2. Bair SM, Choueiri T, **Moslehi J**. Cardiovascular Complications Associated with Novel Angiogenesis Inhibitors: Emerging Evidence and Evolving Perspectives. **Trends Cardiovascular Medicine**. 2013;23(4):104-13. PMID: 23290365
3. **Moslehi J**. The Cardiovascular Perils of Cancer Survivorship. **New England Journal of Medicine**. 2013;368(11):1055-6. PMID: 23484833

4. Groarke JD...Cheng S, **Moslehi J**. Cardiovascular Complications of Radiation Therapy for Thoracic Malignancies: The Role for Non-Invasive Imaging for Detection of Cardiovascular Disease. *Eur Heart J*. 2014;35(10):612-23. PMID: 23666251
5. **Moslehi J**, Cheng S. Cardio-Oncology: It Takes Two to Translate. *Science Translational Medicine*. 2013;5(187):187fs20. PMID: 23720578
6. Ky B...Force T, **Moslehi J**. Emerging Paradigms in Cardiomyopathies Associated with Cancer Therapies. *Cir Res*. 2013;113(6):754-64. PMID: 23989717
7. Groake JD, Cheng S, **Moslehi J**. Cancer-Drug Discovery and Cardiovascular Surveillance. *New England Journal of Medicine*. 2013;369(19):1779-81. PMID: 24180496
8. Koelwyn GJ, Jones LW, **Moslehi J**. Unravelling the Causes of Reduced Peak Oxygen Consumption in Patients with Cancer: Complex, Timely, and Necessary. *J Am Coll Card*. 2014;64(13):1320-2. PMID: 25257632
9. Montazeri K...Partridge AH, **Moslehi J**. ABCDE Steps to Prevent Heart Disease in Breast Cancer Survivors. *Circulation*. 2014;130(18):e157-9. PMID: 25462826
10. Li W...**Moslehi J**. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies. *J Am Coll Card*. 2015;66(10):1160-78. PMID: 26337996
11. **Moslehi J**, Deininger M. Tyrosine Kinase Inhibitor Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. *J Clin Oncol*. 2015;33(35):4210-8. PMID: 26371140
12. Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, **Moslehi J**. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. *Circulation*. 2015;132(23):2248-58. PMID: 26644247
13. Bhatia N...Morgans AK, **Moslehi J**. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients with Prostate Cancer. *Circulation*. 2016;133(5):537-41. PMID: 26831435
14. Li W...Piazza G, **Moslehi J**. Cardiovascular Complications of Novel Multiple Myeloma Treatments. *Circulation*. 2016;133(9):908-12. PMID: 26927008
15. Li W...Richardson PG, **Moslehi J**. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. *JAMA Oncol*. 2016;3(7):980-988. PMID: 27632640
16. **Moslehi JJ**. Cardiovascular Toxic Effects of Targeted Cancer Therapies. *New England Journal of Medicine*. 2016;375(15):1457-1467. PMID: 27732808
17. **Moslehi J**, Amgalan D, Kitsis RN. Grounding Cardio-Oncology in Basic and Clinical Science. *Circulation*. 2017;136(1):3-5. PMID: 28674089
18. Sheng CC...**Moslehi J**. 21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine. *JACC: BTS*. 2016;1(5):386-398. PMID: 28713868
19. Pandey AK...**Moslehi J**. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. *Hypertension*. 2018;71(2):e1-e8. PMID: 29279311
20. Lyon AR...**Moslehi J**, Larkin J. Immune Checkpoint Inhibitors and Cardiovascular Toxicity. *Lancet Oncology*. 2018;19(9):e447-e458. PMID: 30191849
21. Hu JR...Johnson DB, **Moslehi J**. Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors. *Cardiovascular Research*. 2019;115(5):854-868. PMID: 30715219
22. **Moslehi J**, Fujiwara K, Guzik T. Cardio-Oncology: A Novel Platform for Basic and Translational Cardiovascular Investigation Driven by Clinical Need. *Cardiovascular Research*. 2019;115(5):819-823. PMID: 30888396

23. **Moslehi JJ**, Brinkley DM, Meijers WC. Fulminant Myocarditis: Evolving Diagnosis, Evolving Biology, Evolving Prognosis. *J Am Coll Cardiol*. 2019;74(3):312-314. PMID: 31319913
24. Libby P...**Moslehi J**...Ebert BL. Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019;74(4):567-577. PMID: 31345432
25. Meijers WC, **Moslehi JJ**. Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients with Cancer. *JAMA*. 2019;322(18):1775-1776. PMID: 31714975
26. **Moslehi J**, Rathmell WK. The 2019 Nobel Prize Honors Fundamental Discoveries in Hypoxia Response. *Journal of Clinical Investigation*. 2020 Jan 2;130(1):4-6. PMID: 31763994
27. Manouchehri A...**Moslehi J**. Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care. *ATVB*. 2020;40(2):301-308. PMID: 31875699
28. Hu JR...**Moslehi JJ**. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses. *ATVB*. 2020;40(3):e55-e64. PMID: 31969015
29. Waliyany S...**Moslehi JJ**, Zhu H (\*Co-Senior/Co-Corresponding). Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. *Annu Rev Pharmacol Toxicol*. 2020;142(5):423-425. PMID: 32776859
30. **Moslehi J**, Zhang Q, Moore KJ. Crosstalk Between the Heart and Cancer: Beyond Drug Toxicity. *Circulation*. 2020;142(7):684-687. PMID: 32804565
31. Geraud A...**Moslehi JJ**, Johnson DB, Salem JE. Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. *Annu Rev Pharmacol Toxicol*. 2021;61:85-112. PMID: 32871087
32. Ratain MJ, **Moslehi JJ**, Lichter AS. Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation. *JAMA Oncol*. 2021;7(2):177-178. PMID: 33237281
33. **Moslehi JJ**, Witteles RM. Global Longitudinal Strain in Cardio-Oncology. *J Am Coll Cardiol*. 2021;77(4):402-404. PMID: 33509396
34. **Moslehi J**, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune Checkpoint Inhibitor-Associated Myocarditis: Manifestations and Mechanisms. *J Clin Invest*. 2021;131(5):e145186. PMID: 33645548
35. Baik AH...**Moslehi JJ**. Mechanisms of Cardiovascular Toxicities Associated with Immunotherapies. *Circ Res*. 2021;128(11):1780-1801. PMID: 33934609
36. Fleming MR...**Moslehi JJ**. Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. *Circ Res*. 2021;128(12):1973-1987. PMID:34110908
37. Jing Y, Yang J, Johnson DB\*, **Moslehi JJ\***, Han L\* (\*Co-corresponding). Harnessing big data to characterize immune-related adverse events. *Nat Rev Clin Oncology*. 2022;19:269-280. PMID: 35039679
38. Johnson DB, Nebhan CA, **Moslehi JJ**, Balko JM. Immune checkpoint inhibitors: long-term implications of toxicity. *Nat Rev Clin Oncology*. 2022;19:254-267. PMID: 35082367
39. Karlstaedt A, **Moslehi J\***, De Boer RA\* (\*Co-Senior/Co-Corresponding). Cardio-onco-metabolism: metabolic remodeling in cardiovascular disease and cancer. *Nat Rev Cardiology*. 2022;19:414-425. PMID: 35440740
40. Wyant GA, Moslehi J. Expanding the Therapeutic World of Tryptophan Metabolism. *Circulation*. 2022;145(24):1799-1802. PMID: 35696459
41. Moslehi J, Salem JE. Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions. *JACC: CardioOncology*. 2022. 4:704-707. PMID: 36636442

42. Ammirati E, Moslehi J. Diagnosis and Treatment of Acute Myocarditis. JAMA. 2023. 2023;329:1098-1113. PMID: 37014337

### **Patient Guideline Documents**

#### Most Significant:

1. Campia U, **Moslehi JJ**...Weintraub NL. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association. Circulation. 2019;139(13):e579-e602. PMID: 30786722
2. Kociol RD...**Moslehi JJ**...Vardeny O. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement from the American Heart Association. Circulation. 2020;141(6):e69-e92. PMID: 31902242
3. Denlinger CS, Sanft T, **Moslehi J**...Freedman-Cass DA. NCCN Guidelines Insights: Survivorship, Version 2.2020. JNCCN. 2020. PMID: 32755975
4. de Boer RA...**Moslehi JJ**...Bucks J. Common Mechanistic Pathways in Cancer and Heart Failure. A Scientific Road Map on Behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(12):2272-2289. PMID: 33094495
5. Ammirati E...**Moslehi JJ**...Camici PG. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circulation: Heart Failure. 2020;13(11):e007405. PMID: 33176455
6. Asnani A, **Moslehi JJ**...Zhu H. Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement from the American Heart Association. Circ Res. 2021;129(1):e21-e34. PMID: 33934611
7. Tevaarwerk A...**Moslehi JJ**...Freedman-Cass DA. Survivorship, Version 1.2021. JNCCN. 2021;19(6):676-685. PMID: 34214969
8. Zaha VG...**Moslehi JJ**, Shah, SH. Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. Circulation. 2021. PMID: 34753300
9. Lyon AR...**Moslehi J**...van der Pal HJH. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022. PMID: 36017568

### **Invited Presentations**

#### **National**

- 2006 Beyond Erythropoiesis: EPO, Cognition, and Cardiac Surgery  
Harvard Medical School, Brigham and Women's Hospital  
Cardiovascular Clinical: Conference  
Boston, MA
- 2007 Pitfalls in Vascular Ultrasound  
American College of Cardiology: Annual Meeting  
New Orleans, LA
- 2008 An Unexpected Role for Hypoxia-Inducible Factor (HIF) in Cardiomyopathy  
Harvard Medical School, Brigham and Women's Hospital  
Cardiovascular: Clinical Conference  
Boston, MA
- 2009 Sensing Hypoxia in Heart: Prolyl Hydroxylases (PHDS), HIF

- Harvard Medical School, Brigham and Women's Hospital  
Cardiomyopathy Cardiovascular: Clinical Conference  
Boston, MA
- 2010 Angiogenesis Inhibitors and the Cardiovascular System  
M.D. Anderson: 1<sup>st</sup> Cancer and the Heart Conference  
Houston, TX
- 2010 Cardiac-Specific Loss of Prolyl Hydroxylases (PHDs) Phenocopies Ischemic  
Cardiomyopathy  
Keystone Conference: Angiogenesis in Health and Disease  
Keystone, CO
- 2010 Loss of PHD Prolyl Hydroxylase Activity and Ischemic Cardiomyopathy  
Heart Failure Society of America (HFSA): Annual Meeting  
San Diego, CA
- 2010 The Use of HIF Prolyl Hydroxylase Inhibitors in Treated Ischemic Cardiac Disease  
American Heart Association  
Vascular Biology Working Group: Global Chapter Meeting  
Chicago, IL
- 2010 Cardiovascular Toxicities of Novel Breast Cancer Chemotherapies: Lessons from Bench  
to Bedside  
Harvard Medical School, Dana-Farber Cancer Institute: Breast Cancer Group Meeting  
Boston, MA
- 2011 Cardio-Oncology: A New Cardiovascular Frontier  
American Heart Association: Vascular Biology Working Group Global Chapter Meeting  
Orlando, FL
- 2011 Cardiovascular Toxicities of VEGF Inhibitors in Kidney Cancer Treatment  
Beth Israel Deaconess Medical Center  
Harvard Medical School, Dana-Farber: Kidney Cancer Program Meeting  
Boston, MA
- 2012 VEGF Inhibitors and the Heart  
M.D. Anderson: 2<sup>nd</sup> Cancer and the Heart Conference  
Houston, TX
- 2012 Cardiovascular Complications and Neuro-Oncology Chemotherapies  
Harvard Medical School, Massachusetts General Hospital Neuro-Oncology: Grand  
Rounds  
Boston, MA
- 2012 Cardio-Oncology: A New Cardiovascular Frontier  
Medical College of Wisconsin: Cardiology Grand Rounds  
Milwaukee, WI
- 2012 Cancer and the Heart  
University of Connecticut School of Medicine: Cardiology Grand Rounds  
Farmington, CT
- 2013 Cardio-Oncology: The Evolving Science  
American College of Cardiology: Annual Meeting  
San Francisco, CA
- 2013 Cardiovascular Toxicities Associated with Novel Angiogenic Therapies: Emerging  
Evidence and Evolving Perspectives  
Joint NCI/NHLBI Symposium in Cancer Treatment Related Cardiotoxicity  
Rockville, MD
- 2013 The Cardiovascular Perils of Cancer Survivorship  
American College of Physicians: Annual Meeting  
San Francisco, CA



- 2013 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Heart Failure Society of America (HFSA): Annual Meeting  
Orlando, FL
- 2013 Mechanisms of Cardiotoxicity: Insight into Aging  
National Cancer Institute: Mechanisms of Accelerated Aging  
Rockville, MD
- 2013 Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer  
American Heart Association: Annual Meeting  
Dallas, TX
- 2014 Cardiovascular Effects of Targeted Cancer Therapies: Insight into drug discovery  
Millenium/Takeda: Medical Grand Rounds  
Cambridge, MA
- 2014 Hypoxia, HIF and Cardio-Oncology  
University of California, San Francisco School of Medicine: Cardiology Grand Rounds  
San Francisco, CA
- 2014 Cardio-Oncology: A New Clinical Frontier  
University of California, San Diego School of Medicine: Cardiology Grand Rounds  
San Diego, CA
- 2014 Eglns, HIF and the Heart  
University of California, San Diego School of Medicine Grand Rounds: Cardiovascular  
Research Institute  
San Diego, CA
- 2014 Cardio-Oncology: A Novel Platform to Understand Cardiomyopathies  
American Heart Association: Annual Meeting  
Chicago, IL
- 2014 Anthracycline Associated Cardiotoxicity  
National Comprehensive Cancer Network Panel Meeting  
Philadelphia, PA
- 2014 The Cardiovascular Safety of Novel Tyrosine Kinase Inhibitors  
M.D. Anderson: 3<sup>rd</sup> Cancer and the Heart Conference  
Houston, TX
- 2015 Cardio-Oncology: A New Clinical Frontier  
Heart and Vascular Institute of Greater Sacramento: Medicine Grand Rounds  
Sacramento, CA
- 2015 Cardiac Ischemia and Angiogenesis Inhibitors Used for Cancer Therapy  
American College of Cardiology: Annual Meeting  
San Diego, CA
- 2015 Vascular Toxicities Associated with Tyrosine Kinase Inhibitors in CML  
Great Debates in Hematologic Malignancies  
New York, NY
- 2015 Mechanisms of Cardiotoxicities with Novel Cancer Therapies  
American Society of Echocardiography: Annual Meeting  
Boston, MA
- 2015 Cardiovascular Assessment of Novel Cancer Therapies  
United States Federal Drug Administration  
Silver Springs, MD
- 2015 Cardio-Oncology: Evolving Principles  
Medical College of Wisconsin: Cardiology Grand Rounds  
Milwaukee, WI
- 2015 Cancer and Thrombosis  
American Heart Association: Annual Meeting

- Chicago, IL
- 2015 Cardiovascular Toxicities of Tyrosine Kinase Inhibitors  
American Heart Association: Annual Meeting  
Orlando, FL
- 2015 NCCN: Cardio-Oncology Guidelines  
National Comprehensive Cancer Network Panel Meeting  
Philadelphia, PA
- 2015 Cardio-Oncology: A New Clinical Frontier  
California Pacific Medical Center: Cardiology Grand Rounds  
San Francisco, CA
- 2016 Cardio-Oncology: A New Clinical Frontier  
University of Minnesota School of Medicine: Oncology Grand Rounds  
Minneapolis, MN
- 2016 Cardio-Oncology: Hypoxic Signaling, HIF and Cardio-Oncology  
University of Minnesota-Lillehei Heart Institute: Lecture  
Minneapolis, MN
- 2016 Cardio-Oncology: Time to Grow Up  
American College of Cardiology: Annual Meeting  
Chicago, IL
- 2016 Cardio-Oncology: A New Clinical Frontier and a Novel Platform for Investigation  
University of Iowa School of Medicine: Cardiology Grand Rounds  
Iowa City, IA
- 2016 Hypoxic Signaling, HIF and Cardio-Oncology  
Stanley J. Sarnoff Foundation Alumni Talk  
Boston, MA
- 2016 Cardio-Oncology: A Novel Platform for Research Investigation  
Rockefeller University: Seminars in Clinical Research  
New York, NY
- 2016 Overview of Cardiovascular Toxicities During Cancer Treatment  
American Society of Clinical Oncology: Annual Meeting  
Chicago, IL
- 2016 Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors Used in Chronic  
Myelogenous Leukemia Treatment  
Society of Hematologic Oncology: Annual Meeting  
Houston, TX
- 2016 Thomas L Force Keynote Lecture: Immunotherapy Associated Myocarditis: A New  
Clinical Entity in Cardio-Oncology  
Heart Failure Society of America (HFSA): Annual Meeting  
Orlando, FL
- 2016 Cardiovascular Toxic Effects of Novel Cancer Therapies: An Overview  
Heart Failure Society of America (HFSA): Annual Meeting  
Orlando, FL
- 2016 How and When Pre-Clinical Test Should be Incorporated Into Cardiotoxicity Testing for  
Novel Cancer Therapies  
FDA Workshop: Cardiotoxicity Assessment in Oncology Trials Workshop  
Baltimore, MD
- 2016 Cardio-Oncology: Clinical and Research Perspectives  
University of California, San Francisco: Sokolow Lectureship  
San Francisco, CA
- 2016 Precision Survivorship in Prostate Cancer  
Prostate Cancer Foundation (PCF): Research Retreat

- San Diego, CA
- 2016 Novel Oral Anti-Coagulants in Oncology  
American Heart Association (AHA): Annual Meeting  
New Orleans, LA
- 2016 Cancer and Thrombosis  
American Heart Association (AHA): Annual Meeting  
New Orleans, LA
- 2016 Cardio-Oncology: A New Medical Discipline  
University of South Florida: Cardiology Grand Rounds  
Tampa, FL
- 2017 Cardio-Oncology: A New Medical Discipline  
Mayo Clinic: Internal Medicine Grand Rounds  
Phoenix, AZ
- 2017 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Northwestern University: Lurie Cancer Center Grand Rounds  
Chicago, IL
- 2017 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
University of Alabama Medical School: Cancer Center Grand Rounds  
Birmingham, AL
- 2017 Cardio-Oncology: A New Frontier in Clinical Medicine  
Florida Heart and Vascular Network: Grand Rounds  
Boca Raton, FL
- 2017 Cardio-Oncology: A New Frontier in Clinical Medicine  
San Antonio Heart Failure: Symposium  
San Antonio, TX
- 2017 Cardio-Oncology: A New Clinical Frontier  
George Washington University: Cardiology Grand Rounds  
Washington, DC
- 2017 Cardio-Oncology: Cardiovascular Health in Cancer Survivors  
National Cancer Center Network: Annual Meeting  
Orlando, FL
- 2017 Cardiovascular Toxicities Associated with Immune-Checkpoint Blockade  
American Association of Cancer Research: Annual Meeting  
Washington, DC
- 2017 Immune Checkpoint-Inhibitor Associated Myocarditis  
American Autoimmune Related Disease Association: Annual Meeting  
Washington, DC
- 2017 Cardiotoxicity of Novel Cancer Therapies  
Memorial Sloan-Kettering Cancer Center: Cardio-Oncology Symposium  
New York, NY
- 2017 21<sup>st</sup> Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Precision  
Medicine  
Applied Pharmaceutical Toxicology: Annual Meeting  
San Francisco, CA
- 2017 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Johns Hopkins Medical School: Cardiology Grand Rounds  
Baltimore, MD
- 2017 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Main Medical Center Research Institute: Seminar  
Portland, ME
- 2017 Cardio-Oncology: A Novel Platform for Basic and Translational Research

- Yale Medical School: Cardiology Grand Rounds  
New Haven, CT
- 2017 Immune Checkpoint Inhibitor Associated Myocarditis: Defining a New Clinical Syndrome  
Bladder Cancer Advocacy Network: Think Tank  
Charlotte, NC
- 2017 The Revolution in the Development of Targeted Cancer Therapies  
Heart Failure Society of America (HFSA): Annual Meeting  
Dallas, TX
- 2017 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
University of Rochester: Cardiology Grand Rounds  
Rochester, NY
- 2017 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Mayo School of Medicine: Cancer Seminar Series  
Jacksonville, FL
- 2017 What Cardiovascular Toxicities are Germane to Oncology Drug Development?  
Cardiac Safety Research Consortium Think Tank: Assessment and Risk Mitigation of  
Cardiac Safety Signals in Oncology Drug Development  
Silver Springs, MD
- 2017 NCCN: Cardio-Oncology Survivorship Guidelines  
National Comprehensive Cancer Network: Panel Meeting  
Philadelphia, PA
- 2017 Hypoxia Inducible Factors  
American Heart Association (AHA): Annual Meeting  
Anaheim, CA
- 2017 Cardio-Oncology: Mechanisms of Cardiotoxicity  
American Heart Association (AHA): Annual Meeting  
Anaheim, CA
- 2017 Clinician and Researcher Role in Social Media  
American Heart Association (AHA): Annual Meeting  
Anaheim, CA
- 2017 Thrombotic Complications of Cancer Drugs  
American Heart Association (AHA): Annual Meeting  
Anaheim, CA
- 2017 Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors  
FDA Workshop: Assessment of Cardiovascular Toxicities in Immuno-Oncology Trials  
Chevy Chase, Maryland
- 2017 Pathophysiology of Immune Checkpoint Inhibitor Associated Myocarditis  
FDA Workshop: Assessment of Cardiovascular Toxicities in Immuno-Oncology Trials  
Chevy Chase, Maryland
- 2017 Cardiovascular Complications in Chronic Myelogenous Leukemia  
American Society of Hematology (ASH): Annual Meeting  
Atlanta, GA
- 2017 Basic and Clinical Understanding of Immunotherapy Inhibitor Associated Myocarditis  
Project Data Sphere Symposium on Immune Checkpoint Associated Myocarditis  
Peapack, NJ
- 2018 Cardio-Oncology: How Targeted Cancer Therapies and Precision Medicine Can Inform  
Cardiovascular Discovery  
Yale School of Medicine: Immuno-Biology Symposium  
New Haven, CT
- 2018 Cardio-Oncology: A New Clinical Frontier  
Houston Methodist Hospital: Cardiology Grand Rounds

- Houston, TX
- 2018 The Revolution in the Development of Targeted Cancer Therapies  
Mayo Clinic School of Medicine (AZ): Cardio-Oncology Symposium  
Scottsdale, AZ
- 2018 Immunotherapy-Induced Myocarditis: Defining a New Clinical Syndrome  
Mayo Clinic School of Medicine (AZ): Cardio-Oncology Symposium  
Scottsdale, AZ
- 2018 Prostate Cancer Therapies and Cardio-Oncology  
ACC Advancing CV Care of the Oncology Patient: Cardio-Oncology Symposium  
Washington, DC
- 2018 NCCN Guidelines: Cardio-Oncology  
ACC Advancing CV Care of the Oncology Patient: Cardio-Oncology Symposium  
Washington, DC
- 2018 Immunotherapy-Induced Myocarditis: Defining a New Clinical Syndrome  
ACC Advancing CV Care of the Oncology Patient: Cardio-Oncology Symposium  
Washington, DC
- 2018 Immunotherapy-Induced Myocarditis: Defining a New Clinical Syndrome  
Vascular Biology Working Group (VBWG): ACC Symposium  
Orlando, FL
- 2018 Peripheral Vascular Disease and Cardio-Oncology  
American College of Cardiology (ACC): Annual Meeting  
Orlando, FL
- 2018 Mechanisms of Immune Checkpoint-Inhibitor Associated Myocarditis  
Parker Institute of Immunotherapy: Directors Meeting  
San Francisco, CA
- 2018 Immunotherapy-Induced Myocarditis: Defining a New Clinical Syndrome  
National Cancer Institute (NCI) Symposium: Cancer, Autoimmunity, and Immunology  
Bethesda, MD
- 2018 Chemotherapy Induced Vascular Toxicity  
Experimental Biology Annual Meeting  
San Diego, CA
- 2018 Immune-Checkpoint Inhibitor Associated Myocarditis  
American Society of Clinical Oncology: Annual Meeting  
Chicago, IL
- 2018 Mechanisms of Cardiotoxicities with Novel Cancer Therapies  
American Society of Echocardiography: Annual Meeting  
Nashville, TN
- 2018 Immune-Checkpoint Inhibitor Associated Myocarditis: Mechanisms  
American Society of Echocardiography: Annual Meeting  
Nashville, TN
- 2018 Vascular Cardio-Oncology: Mechanisms and Implications Moving Forward  
Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related  
Cardiotoxicity. National Institutes of Health  
Bethesda, MD
- 2018 Immunotherapy and Cardiotoxicity: Staying Ahead of the Curve  
Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related  
Cardiotoxicity. National Institutes of Health  
Bethesda, MD
- 2018 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Washington University: Cardiology Grand Rounds  
St. Louis, MO

- 2018 Cardio-Oncology: A Novel Platform for Research Investigation  
University of Texas, Houston: James T. Willerson Cardiovascular Science Seminars  
Houston, TX
- 2018 Immune-Checkpoint Inhibitor Associated Myocarditis: Diagnosis and Mechanisms  
Heart Failure Society of America (HFSA): Annual Meeting  
Nashville, TN
- 2018 Identifying Cardiac Safety Signals in the Era of Personalized Medicine  
American College of Clinical Pharmacology: Annual Meeting  
Bethesda, MD
- 2018 Developing a Formal Cardio-Oncology Fellowship and Educational Curriculum  
Global Cardio-Oncology Summit  
Tampa, FL
- 2018 Cardio-Oncology: A New Clinical Frontier  
University of Maryland Medical School: Cardiology Grand Rounds  
Baltimore, MD
- 2018 Vascular Cardio-Oncology: Extreme Hypercoagulability in Cancer  
American Heart Association (AHA): Annual Meeting  
Chicago, IL
- 2018 Current Challenges in Cardio-Oncology  
American Heart Association (AHA): Annual Meeting  
Chicago, IL
- 2018 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Cedars-Sinai Medical Center: Cardiology Grand Rounds  
Los Angeles, CA
- 2018 Cancer and the Heart: It Is Pretty Bad  
Northwestern Annual Heart Failure Holiday Symposium  
Chicago, IL
- 2018 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
University of Colorado School of Medicine: Cardiology Grand Rounds  
Denver, CO
- 2018 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
University of Pittsburgh School of Medicine: Cardiology Grand Rounds  
Pittsburgh, PA
- 2019 HIF, VEGF and PD-1: What Cancer Can Teach Us About Cardiovascular Disease  
Northwestern School of Medicine: Cardiology Grand Rounds  
Chicago, IL
- 2019 Cardio-Oncology: A New Clinical Frontier  
Northwestern School of Medicine: Internal Medicine Grand Rounds  
David P. Earle Memorial Lecturer  
Chicago, IL
- 2019 Historical Overview of Cardio-Oncology: Insights into novel cardiovascular signaling  
Bristol-Myers Squibb: Grand Rounds  
Lawrence Township, NJ
- 2019 HIF, VEGF and PD-1: What Cancer Can Teach Us About Cardiovascular Disease  
University of Chicago School of Medicine: Cardiology Grand Rounds  
Chicago, IL
- 2019 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
University of Texas, Southwestern: Cardiology Grand Rounds  
Dallas, TX
- 2019 Effects of Cancer Therapeutics on Blood Vessels: Biological Mechanisms  
American College of Cardiology (ACC): Annual Meeting

- New Orleans, LA
- 2019 Immune-Checkpoint Inhibitor Associated Myocarditis: Diagnosis and Mechanisms  
American College of Cardiology (ACC): Annual Meeting  
New Orleans, LA
- 2019 Immune-Checkpoint Inhibitor Associated Myocarditis: From Bench to Bedside  
Experimental Biology Annual Meeting: American Society of Investigative Pathology  
Orlando, FL
- 2019 Immuno-Oncology and the Heart  
Southwestern Oncology (SWOG) Cancer Research Network Meeting  
San Francisco, CA
- 2019 Immune-Checkpoint Inhibitor Associated Myocarditis: Diagnosis and Treatment  
Memorial Sloan-Kettering Cancer Center: Cardio-Oncology Symposium  
New York, NY
- 2019 Immune-Checkpoint Inhibitor Associated Myocarditis  
American Society of Clinical Oncology: Annual Meeting  
Chicago, IL
- 2019 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Dartmouth-Hitcock Medical Center: Cardiology Grand Rounds  
Hanover, NH
- 2019 Cardio-Oncology: A New Clinical Frontier  
Rush School of Medicine: Internal Medicine Grand Rounds  
Chicago, IL
- 2019 Immunotherapy-Associated Myocarditis: From Bench to Bedside  
American Heart Association (AHA): Basic Science (BCVS) Annual Meeting  
Boston, MA
- 2019 Immune-Checkpoint Inhibitor Associated Myocarditis: Diagnosis and Mechanisms  
Heart Failure Society of America (HFSA): Annual Meeting  
Philadelphia, PA
- 2019 HIF, VEGF and PD-1: What Cancer Can Teach Us About Cardiovascular Disease  
Cleveland Clinic: Cardiology Grand Rounds  
Cleveland, OH
- 2019 Cardio-Oncology: A New Clinical Frontier  
Cleveland Clinic: Internal Medicine Grand Rounds  
Cleveland, OH
- 2019 Precision Survivorship in Prostate Cancer: Impact of Immunotherapies  
Prostate Cancer Foundation (PCF): Research Retreat  
San Diego, CA
- 2019 Immune-Checkpoint Inhibitor Associated Myocarditis: Diagnosis and Treatment  
Memorial Sloan-Kettering Cancer Center: Immunotherapy Symposium  
New York, NY
- 2019 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Medical College of Wisconsin: Cardiology Research Seminar Series  
Milwaukee, WI
- 2019 Cardio-Oncology: The Basics  
Chemotherapy Foundation Symposium  
New York, NY
- 2019 Immune-Checkpoint Inhibitor (ICI)-Associated Myocarditis: Diagnosis and Treatment  
Kidney Cancer Association Annual Meeting  
Miami, FL
- 2019 Immune-Checkpoint Inhibitor (ICI)-Associated Myocarditis: Novel Treatment Strategies  
American Heart Association (AHA): Annual Meeting

- Philadelphia, PA
- 2019 Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis: Of Mice and Men  
American Association of Cancer Research (AACR): Tumor Immunotherapy  
Boston, MA
- 2019 Cardiovascular Toxicities Associated with Immune-Checkpoint Blockade  
Harvard Cancer Center Immunotherapy Toxicity Symposium  
Boston, MA
- 2019 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Mayo, Jacksonville: Cardiology Grand Rounds  
Jacksonville, FL
- 2020 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Stanford Cardiovascular Research Institute: Research Seminar Series  
Palo Alto, CA
- 2020 Cardio-Oncology: A New Clinical Frontier and a Novel Platform for Investigation  
New York University School of Medicine: Research Seminar Series  
New York, NY
- 2020 Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis: Of Mice and Men  
Keystone Symposia: Charting a New Course for Heart Failure  
Keystone, CO
- 2020 Cardio-Oncology: A New Clinical Frontier  
University of California, San Francisco School of Medicine: Cardiology Grand Rounds  
San Francisco, CA (\*Virtual)
- 2020 Cardio-Oncology: A Novel Platform for Cardiovascular Investigation  
UCSF Cardiovascular Research Institute (CVRI): Grand Rounds  
San Francisco, CA (\*Virtual)
- 2020 Cardio-Oncology: A New Medical Discipline  
Mayo Clinic: Cardiology Grand Rounds  
Phoenix, AZ (\*Virtual)
- 2020 Cardio-Oncology: A New Clinical Frontier in Hematology  
University of Washington: Hematology Division Grand Rounds  
Seattle, WA (\*Virtual)
- 2020 Ibrutinib and Other BTK Inhibitors: Cardiovascular Sequelae  
International Summit on Interventional Pharmacoeconomics  
Chicago, IL (\*Virtual)
- 2020 Cardio-Oncology: A New Clinical Frontier in Hematology  
University of Washington: Fred Hutchinson Clinical Research Seminar Series  
Seattle, WA (\*Virtual)
- 2020 Cardio-Oncology: Cardiovascular Sequelae of Cancer Immunotherapies  
Dana-Farber Cancer Institute/Harvard Cancer Center: Connect: Science Seminar  
Boston, MA (\*Virtual)
- 2020 Cardio-Oncology: A New Clinical and Research Frontier  
University of California, San Francisco School of Medicine: Hematology Grand Rounds  
San Francisco, CA (\*Virtual)
- 2020 Why Every Heart Failure Doctor Needs to Learn about Cancer Immunotherapies  
Heart Failure Society of America (HFSA): Annual Meeting  
Cleveland, OH (\*Virtual)
- 2020 Cardio-Oncology: A New Clinical Frontier and a Novel Platform for Investigation  
New York University School of Medicine: Internal Medicine Grand Rounds  
New York, NY (\*Virtual)
- 2020 Cardio-Oncology as a Novel Platform for Drug Discovery  
Amgen Grand Rounds: Department of Safety and Bioanalytical Sciences



- South San Francisco, CA (\*Virtual)
- 2020 Anti-VEGF Therapies and Hypertension: Mechanisms  
American Society of Nephrology: Annual Meeting  
Denver, CO (\*Virtual)
- 2020 Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research  
M.D. Anderson: Multidisciplinary Grand Rounds  
Houston, TX (\*Virtual)
- 2020 Integrating Cardio-Oncology Expertise in Cancer Treatment and Survivorship Care  
National Academy of Sciences, Engineering and Medicine: National Cancer Forum  
Washington, DC (\*Virtual)
- 2020 Interconnected Systems: Lessons from Probing the Cardio-Immuno-Oncologic Interface  
American Heart Association (AHA): Annual Meeting  
Dallas, TX (\*Virtual)
- 2020 Anti-Angiogenic Therapy and Vascular Defects  
American Heart Association (AHA): Annual Meeting  
Dallas, TX (\*Virtual)
- 2020 Cardiac Complications in the Modern Era of Immunotherapy for Cancer Treatment  
American Heart Association (AHA): Annual Meeting  
Dallas, TX (\*Virtual)
- 2020 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Cedars-Sinai Medical Center: Medical Oncology Grand Rounds  
Los Angeles, CA (\*Virtual)
- 2020 Cardiovascular Sequelae of Cancer Immunotherapies: A systems-based approach  
University of Texas, Houston: Biochemistry and Molecular Biology Seminar Series  
Houston, TX (\*Virtual)
- 2021 Immune Checkpoint Inhibitor-Associated Myocarditis: Learning from Mice and Humans  
Dana-Farber Cancer Institute (DFCI): Center for Immuno-Oncology: Grand Rounds  
Boston, MA (\*Virtual)
- 2021 Cardio-Oncology: A Novel Platform for Cardiovascular Investigation  
Massachusetts General Hospital (MGH) CVRC: Grand Rounds  
Boston, MA (\*Virtual)
- 2021 Cardio-Oncology: A New Clinical Frontier and a Novel Platform for Investigation  
University of California, Los Angeles (UCLA): Cardiology Grand Rounds  
Los Angeles, CA (\*Virtual)
- 2021 Cardio-Oncology: A New Clinical Frontier and a Novel Platform for Investigation  
Beth Israel Deaconess Medical Center (BIDMC): Cardiology Grand Rounds  
Boston, MA (\*Virtual)
- 2021 What Should Practicing Hematologists/Oncologists Know About Cardiotoxicity  
Great Debates in Hematologic Malignancies  
\*Virtual
- 2021 Cancer Immunotherapy-Associated Myocarditis: Teaching us about Heart Autoimmunity  
American College of Rheumatology: Clinical Symposium  
\*Virtual
- 2021 Immune Checkpoint Inhibitor-Associated Myocarditis: Learning from Mice and Humans  
National Heart, Lung, and Blood Institute (NHLBI): Challenges of Myocarditis  
\*Virtual
- 2021 Targeted Therapies, Immunotherapies and Cardiotoxicity  
American College of Cardiology (ACC): Annual Meeting  
\*Virtual
- 2021 The Many Faces of Myocarditis

- American College of Cardiology (ACC): Annual Meeting  
\*Virtual
- 2021 Cardio-Oncology: A New Clinical Frontier in Cardiology  
Christiana Care Health System: Cardiology Grand Rounds  
Newark, DE (\*Virtual)
- 2021 Cardio-Immunology is the New Cardio-Oncology  
American Heart Association (AHA): Basic Science (BCVS) Annual Meeting  
\*Virtual
- 2021 Cancer and Heart Failure: Shared Mechanisms  
Heart Failure Society of America (HFSA): Annual Meeting  
Denver, CO
- 2021 Immunotherapy and Cardiotoxicity  
Heart Failure Society of America (HFSA): Annual Meeting  
Denver, CO
- 2021 Cardio-Immunology is the New Cardio-Oncology  
Current Paradigms in Cardiovascular Care of the Cancer Patient: Rush  
Chicago, IL (\*Virtual)
- 2021 Cardio-Oncology: A New Clinical Frontier in Cardiology  
Boston University Medical Center: Cardiology Grand Rounds  
Boston, MA (\*Virtual)
- 2021 How to Join the Path of Discovery in Cardio-Oncology  
American Heart Association (AHA): Annual Meeting  
Boston, MA (\*Virtual)
- 2022 Cardio-Oncology: A New Clinical Frontier and a Novel Platform for Investigation  
University of Buffalo: Department of Pharmacology & Toxicology Seminar Series  
Buffalo, NY (\*Virtual)
- 2022 Immunotherapy-Associated Cardiotoxicity: Where are we going?  
Ohio State University: Cardio-Oncology Symposium  
Columbus, OH (\*Virtual)
- 2022 Cardio-Oncology: A New Clinical Frontier in Cardiology  
Case Western University: Cardiology Grand Rounds  
Cleveland, OH (\*Virtual)
- 2022 Immune Checkpoint Inhibitors: The Good, the Bad, and the Ugly  
UCSF: Medicine Grand Rounds  
San Francisco, CA
- 2022 Cardiac Complications of Immune Checkpoint Inhibitors  
American Society of Clinical Oncology: Annual Meeting  
Chicago, IL
- 2022 Immune Checkpoints and the Heart  
Gordon Research Conference: Cardiac Regulatory Mechanisms  
New London, NH
- 2022 Immune Checkpoint-Inhibitor Associated Cardiotoxicity: From Mice to Humans  
2022 MD Anderson Immune Oncology (IO) Toxicity Research Retreat  
Houston, TX (\*Virtual)
- 2022 Cardio-Oncology: A Novel Platform for Cardiovascular Investigation  
Tufts Medical Center Molecular Cardiology Research Institute (MCRI) Retreat  
Woods Hole, MA
- 2022 Immune Checkpoint-Inhibitor Associated Cardiotoxicity: From Mice to Humans  
MD Anderson Department of Molecular and Cellular Oncology, Guest Speaker  
Houston, TX (\*Virtual)
- 2022 Immune Checkpoint-Inhibitor Associated Cardiotoxicity: From Mice to Humans

- MD Anderson Department of Molecular and Cellular Oncology, Guest Speaker  
Houston, TX (\*Virtual)
- 2022 Cardio-Oncology: A Novel Platform for Cardiovascular Investigation  
University of Utah: CVRTI Guest Speaker  
Salt Lake City, UT
- 2022 Cardio-Oncology: A New Clinical Frontier  
University of Utah: Tsagaris Endowed Lectureship (CV Grand Rounds)  
Salt Lake City, UT
- 2022 Cardiovascular Adverse Events of BTK Inhibitors  
Lymphoma, Leukemia & Myeloma Congress  
New York, NY
- 2022 Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis: Of Mice and Men  
American Association of Cancer Research (AACR): Tumor Immunology  
Boston, MA
- 2022 Vascular Cardio-Oncology  
North American Thrombosis Forum  
Boston, MA
- 2022 Cardiovascular Complications from Immunotherapy  
University of Alabama Cardiovascular Symposium  
Birmingham, AL (\*Virtual)
- 2022 Cardiovascular Survivorship Considerations in Lymphoma  
American Society of Hematology (ASH): Annual Meeting  
New Orleans, LA
- 2023 Cardio-Oncology: A Novel Platform for Cardiovascular Investigation  
Baylor College of Medicine: Distinguished Guest Lecturer  
Houston, TX
- 2023 Cardiovascular Complications of Cancer Immunotherapies: Underlying Mechanisms  
Regeneron Pharmaceuticals: Medical Grand Rounds  
Tarrytown, NY (\*Virtual)
- 2023 Cardiovascular Complications of Cancer Immunotherapies  
American Society of Clinical Oncology: Annual Meeting  
Chicago, IL
- 2023 Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis: Of Mice and Men  
American Association of Cancer Research (AACR): Kidney Cancer  
Austin, TX
- 2023 Cardio-Oncology: A Novel Platform for Cardiovascular Investigation  
University of Pennsylvania: Cardiovascular Institute (CVI) Seminar Series  
Philadelphia, PA
- 2023 Cardio-Oncology: A New Clinical Frontier  
University of Pennsylvania: Cardiology Grand Rounds  
Philadelphia, PA

### **International**

- 2008 Cardio-Oncology: A New Frontier in Cardiovascular Medicine  
Shiraz University of Medical Sciences: Medicine Grand Rounds  
Shiraz, Iran
- 2014 The Cardiovascular Perils of Cancer Survivorship  
Shiraz University of Medical Sciences  
Sixth Symposium on Updates in CV Diseases with Focus on Extreme of Ages  
Shiraz, Iran
- 2014 Cancer-Drug Discovery and Cardiovascular Surveillance

- Shiraz University of Medical Sciences  
Sixth Symposium on Updates in CV Diseases with Focus on Extreme of Ages  
Shiraz, Iran
- 2014 Cardio-Oncology: A Novel Platform for Basic and Translational Investigation  
Canadian Cardiology Oncology Network  
Ottawa, Canada
- 2014 Cardio-Oncology: A New Frontier in Cardiovascular Medicine  
First International Brazil-USA Cardio-Oncology Conference  
Sao Paulo, Brazil
- 2014 Cardio-Oncology: A New Frontier in Cardiovascular Medicine  
Cardiostim 2014 EHRA Euro space World Congress in Cardiac Electrophysiology  
Nice, France
- 2015 Vascular and Metabolic Considerations in Cardio-Oncology  
SOCESP 2015  
Sao Paulo, Brazil
- 2016 Vascular Considerations in Cardio-Oncology  
Global Cardio-Oncology Summit  
Vancouver, Canada
- 2017 Cardio-Oncology: A New Clinical Frontier  
Chinese Heart Congress  
Beijing, China
- 2017 Immune Checkpoint Inhibitor Associated Myocarditis: Defining a New Clinical Syndrome  
Global Cardio-Oncology Summit (GCOS) Annual Meeting  
London, England
- 2018 Immune Checkpoint Inhibitor Associated Myocarditis: Defining a New Clinical Syndrome  
Pathophysiology of Cardiovascular Complications in Oncology  
Naples, Italy
- 2018 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Federico II University: Department of Translational Medical Sciences Grand Rounds  
Naples, Italy
- 2018 Immune Checkpoint Inhibitor Associated Myocarditis: Defining a New Clinical Syndrome  
International Workshop of Cardio-Oncology: From Research to Clinical Practice  
Naples, Italy
- 2018 BCR-ABL Kinase Inhibitors in CML  
International Workshop of Cardio-Oncology: From Research to Clinical Practice  
Naples, Italy
- 2018 Cardio-Oncology: A New Research Platform  
Printemps de la Cardiologie: Fundamental and Clinical Research  
Montpellier, France
- 2018 Angiogenesis Inhibitors and the Heart  
Second International Colloquium on Cardio-Oncology  
Krakow, Poland
- 2018 Emerging Paradigms in Cardio-Oncology: Immune Checkpoint Inhibitors  
Second International Colloquium on Cardio-Oncology  
Krakow, Poland
- 2018 Why Cardiologists Must Care About Cancer Immunotherapy  
Heart Failure Update 2018  
Toronto, Canada
- 2018 The Role of Immune Checkpoints and the Heart  
Asian Pacific Society of Cardiology Congress (APSC Congress)  
Taipei, Taiwan

- 2018 Cardio-Oncology: Immunotherapies  
Asian Pacific Society of Cardiology Congress (APSC Congress)  
Taipei, Taiwan
- 2018 Immune Checkpoints and the Heart  
European Society of Cardiology: Heart Failure (ESC.HF)  
Vienna, Austria
- 2019 Immunotherapy in Cancer and the Heart: Where Are We?  
French Society of Cardiology (FSC) Annual Meeting  
Paris, France
- 2019 Role of Immune Checkpoints in the Heart  
European Society of Cardiology: Winter Research Meeting, Basic Heart Failure  
Les Diablerets, Switzerland
- 2019 Cancer Pathways and Mechanisms in Tumor Growth and Heart Failure  
European Society of Cardiology: Heart Failure Association  
Brussels, Belgium
- 2019 Immunotherapy in Cancer and the Heart: From Bench to Bedside  
Global Conference on Myositis (GCOM): Annual Meeting  
Berlin, Germany
- 2019 Cardio-Oncology: A Novel Platform for Basic and Translational Research  
Japanese Circulation Society  
Yokohama, Japan
- 2019 Immune-Checkpoint Inhibitor Associated Myocarditis: From Bench to Bedside  
Japanese Circulation Society  
Yokohama, Japan
- 2019 Cardiovascular Toxicities of Immune Checkpoint Inhibitors  
European Society of Cardiology: Heart Failure (ESC.HF)  
Athens, Greece
- 2019 Cardiovascular Side-Effects of Anti-Tumor Drugs  
European Society of Cardiology (ESC): Annual Meeting  
Paris, France
- 2019 Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors (ICI)  
European Society of Cardiology (ESC): Annual Meeting  
Paris, France
- 2019 Challenges in the Long-Term Follow-Up of Cardio-Oncology Patients  
European Society of Cardiology (ESC): Annual Meeting  
Paris, France
- 2019 Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis: Of Mice and Men  
Canadian Cancer Immunotherapy Consortium Annual Meeting  
Toronto, Canada
- 2019 Overview of Targeted Cancer Therapies and Cardiovascular Effects  
Global Cardio-Oncology Summit (GCOS) Annual Meeting  
Sao Paulo, Brazil
- 2019 Social Media in Cardio-Oncology: Impacts, Tips and Cautions  
Global Cardio-Oncology Summit (GCOS) Annual Meeting  
Sao Paulo, Brazil
- 2019 Personalized Cardio-Oncology: Focus on Targeted Therapies  
European Cardio-Oncology Symposium  
Barcelona, Spain (\*Virtual)
- 2019 Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors (ICI)  
European Cardio-Oncology Symposium  
Barcelona, Spain

- 2019 Vascular Cardio-Oncology: Vascular Effects of Targeted Oncology Therapies  
European Angiology/Vascular Medicine Conference  
Milan, Italy (\*Virtual)
- 2020 New Immune Therapies and Cardiovascular Side Effects  
European Society of Cardiology (ESC): Cardiovascular Round Table  
Madrid, Spain
- 2020 Ibrutinib and other Tyrosine Kinase Inhibitors: Effects on the Heart  
International Congress Cardio-Oncology: From Research to Clinical Practice  
Naples, Italy
- 2020 Revolutionizing Cancer Care with Immunotherapy: Toxicities  
International Workshop on Cardio-Oncology  
Naples, Italy
- 2020 Cardiomyopathy Development Following Breast Cancer Treatment: Restratification  
European Society of Cardiology (ESC): Annual Meeting  
Amsterdam, Netherlands (\*Virtual)
- 2020 Can We Prevent Toxicity of Immune Checkpoint Inhibitors?  
European Society of Cardiology (ESC): Annual Meeting  
Amsterdam, Netherlands (\*Virtual)
- 2020 Shared Mechanisms in Heart Failure and Cancer  
European Society of Cardiology (ESC): Annual Meeting  
Amsterdam, Netherlands (\*Virtual)
- 2020 Year in Review: The Evolving Field of Cardio-Oncology  
Virtual Global Cardio-Oncology Summit  
Madrid, Spain (\*Virtual)
- 2020 Efficacy through Safety: Cardiovascular toxicities associated with BTK Inhibitors  
European School of Haematology: Research Conference on CLL  
Paris, France (\*Virtual)
- 2020 Cardio-Oncology: Cardiovascular Sequelae of Cancer Immunotherapies  
3<sup>rd</sup> UCLA-SAHZU (Hangzhou, Zhejiang) Joint Cardiovascular Science Conference  
Hangzhou, China (\*Virtual)
- 2021 Cardiologist Approach to CML Patient  
Israel Society of Cardio Oncology  
Tel-Aviv, Israel (\*Virtual)
- 2021 Management of Cardiovascular Complications of Androgen Deprivation Therapy  
Canadian Urological Association: Annual Meeting  
\*Virtual
- 2021 Cardiotoxicities Associated with Cancer Immunotherapies  
Cardio-Oncology International Forum  
Beijing, China (\*Virtual)
- 2021 Cardio-Immunology is the New Cardio-Oncology  
China Heart Failure Congress 2021  
\*Virtual
- 2021 Cardiovascular Toxicities of Kinase Inhibitors – Case of BTK Inhibitors  
International Workshop on Chronic Lymphocytic Leukemia (iwCLL)  
Krakow, Poland (\*Virtual)
- 2021 Complex Interplay Between Heart Failure and Cancer  
Heart Failure Seoul 2021  
Seoul, South Korea (\*Virtual)
- 2021 Cardio-Immunology is the New Cardio-Oncology  
Qianjiang International Conference of Cardiology (QICC)  
Hangzhou, China (\*Virtual)

- 2021 Cardio-Oncology: Kinase Inhibitors and Insights into Cardiovascular Biology  
Joint SAHZU-UCLA Distinguished Lecture Series in Cardiovascular Discovery  
Hangzhou, China (\*Virtual)
- 2021 Pathogenesis of ICI-Myocarditis  
European Society of Cardiology: Heart Failure Association  
Paris, France (\*Virtual)
- 2022 Immune Checkpoint and the Heart  
European Society of Cardiology: Winter Research Meeting, Basic Heart Failure  
Les Diablerets, Switzerland (\*Virtual)
- 2022 Myocarditis in Cancer Patients  
Hellenic Congress of Heart Failure  
Athens, Greece (\*Virtual)
- 2022 Immune Checkpoint Inhibitor-Associated Myocarditis  
Chinese Conference on Oncology: China Anti-Cancer Association (CACA)  
Shanghai, China (\*Virtual)
- 2022 Cardio-Immuno-Oncology  
Cardioimmunology Zurich 2022  
Zurich, Switzerland
- 2022 Pre-Clinical Models of Cancer-Associated Cardiovascular Toxicity  
5th Annual Meeting of the Japanese Onco-Cardiology Society  
Tokyo, Japan (\*Virtual)
- 2022 Role of T Effector Cells in the heart  
European Society of Cardiology (ESC), Working Group on Myocardial Function  
Brussels, Belgium (\*Virtual)
- 2023 Cardio-Oncology: A New Clinical Frontier  
McGill University School of Medicine: Cardiology Grand Rounds  
Montreal, Canada (\*Virtual)
- 2023 Immune Checkpoint Inhibition and Cardiovascular Toxicity  
European Society of Cardiology (ESC): Annual Meeting  
Amsterdam, Netherlands
- 2023 ICI-Myocarditis: Insights into cardiac-immune crosstalk  
17<sup>th</sup> Qian-Jiang International Cardiovascular Symposium  
Hangzhou, China

**Personal Statement:**

I am a cardiologist and myocyte biologist. My clinical focus is cardio-oncology (the cardiovascular care of cancer patients and cancer survivors). My basic and translational NIH-funded laboratory addresses myocardial responses to various stresses including hypoxia, aging and toxins. Over the last several years, given my clinical interest in cardio-oncology, my laboratory focus has been in delineating the mechanistic underpinnings of cardiovascular toxicities from novel targeted cancer therapies. I believe because of the targeted nature of the toxicities, cardio-oncology can provide insights into novel signaling pathways that are relevant in human cardiovascular biology and pathology. I have maintained a well-funded research program over the last decade. As of October 2023, I have 3 R01 NIH grants where I am a PI or MPI and 4 other NIH R01 grants where I am a co-investigator.

At University of California, San Francisco (UCSF), I am the William Grossman Distinguished Professor of Cardiology and Professor in Residence and Founding Chief of a new section focused on Cardio-Oncology and Immunology. I work closely with cardiologists and oncologists, basic and translational researchers, and clinicians, locally, nationally, and internationally. I have multiple collaborations with industry and regulatory bodies (including the US FDA). In 2019, I was named the first chair of the American Heart Association (AHA) cardio-

oncology subcommittee. At Vanderbilt and UCSF, I established a Graduate Medical Education (GME) approved fellowship training the next generation of physician-scientists in the field of cardio-oncology. I am an elected member of American Society of Clinical Investigation (ASCI).

Since 2016, a major focus of my clinical and research program has been the interaction between the cardiovascular and immune systems. Our group initially described a novel clinical syndrome of fulminant myocarditis that arises from (ICI) immune checkpoint inhibitors (Johnson et al, *NEJM*, 2016). We further defined the clinical characteristics of ICI-associated myocarditis (Moslehi et al, *Lancet*, 2018) and showed that cardiovascular sequelae of ICI include pericarditis, vasculitis, and arrhythmias (Salem et al, *Lancet Oncology*, 2018). My laboratory has generated mouse models that recapitulate these novel syndromes providing novel insights into mechanisms of disease (Wei et al, *Cancer Discovery*, 2021. Yang et al, *STM*. 2022. Axelrod et al, *Nature*. 2022. Ma et al, *Circulation*, 2024). Using these models, we have developed novel therapeutics by targeting immunology nodes and these have proven effective in patients with ICI-myocarditis (Salem et al, *NEJM*, 2019. Salem et al, *Cancer Discovery*, 2023).